<?xml version="1.0" encoding="UTF-8"?>
<p>Cognitive decline is among the most frequent and debilitating nonmotor symptoms of patients with PD with 46% and 83% of surviving patients, at 10 and 20â€‰years postdiagnosis, respectively, having progressed to dementia (PD dementia [PDD]).
 <xref rid="mds28144-bib-0020" ref-type="ref">
  <sup>20</sup>
 </xref>, 
 <xref rid="mds28144-bib-0021" ref-type="ref">
  <sup>21</sup>
 </xref> Notably, patients who carry 
 <italic>GBA</italic> mutations display higher frequencies of cognitive decline and 5 times the risk of progression to dementia relative to patients who do not have 
 <italic>GBA</italic> mutations.
 <xref rid="mds28144-bib-0022" ref-type="ref">
  <sup>22</sup>
 </xref>, 
 <xref rid="mds28144-bib-0023" ref-type="ref">
  <sup>23</sup>
 </xref>, 
 <xref rid="mds28144-bib-0024" ref-type="ref">
  <sup>24</sup>
 </xref>, 
 <xref rid="mds28144-bib-0025" ref-type="ref">
  <sup>25</sup>
 </xref> Postmortem studies indicate that cortical Lewy body pathology is a main pathological correlate of dementia in PD.
 <xref rid="mds28144-bib-0026" ref-type="ref">
  <sup>26</sup>
 </xref>
</p>
